Global CAR-T cell therapy market was valued over USD1081 million in 2020 and is forecast to grow at CAGR of 64.66% through 2027. Growing prevalence of cancer types including, Lymphoma, Leukemia, among others, and increasing research for developing personalized medicine for better response time and highest safety margin are driving the growth of the CAR-T cell therapy market.
The increasing awareness pertaining to CAR-T cell therapies and associated benefits in treating different types of cancer has increased the number of academic & research institutions, hospitals, biotechnology & pharmaceutical companies entering the space for developing more treatments. This has even attracted the attention of governments and government agencies worldwide, and they have started supporting CAR-T cell therapy-based research & development activities either by providing funds or grants. Global CAR-T cell therapy market is segregated based on product type, tumor type, indication, treatment type, target antigen, end user and others.
In terms of different CAR-T cell therapies approved, Yescarta is expected to hold a significantly large market share during the forecast period. This can be ascribed to being among the first approved CAR-T cell therapies in 2017. Yescarta received the initial FDA approval in October 2017. Leading companies operating in the CAR-T cell therapy market include Gilead Sciences, Inc, Novartis International AG, Bristol Myers Squibb Co., AbbVie Inc., Cellectis SA, Amgen Inc, Pfizer Inc., Merck & Co. Inc., Intellia Therapeutics Inc., Poseida Therapeutics Inc, Johnson & Johnson, Allogene Therapeutics Inc, Autolus Therapeutics PLC, Humanigen, Inc. and Sangamo Therapeutics, Inc.